Syndax posted total revenue of USD 68.7 million in Q4 2025 and USD 172.4 million in FY 2025. Q4 revenue included Revuforj net revenue of USD 44.2 million (+38%), Niktimvo collaboration revenue of USD 19.4 million, and milestone, license and royalty revenue of USD 5.1 million; FY 2025 revenue included Revuforj net revenue of USD 124.8 million, Niktimvo collaboration revenue of USD 42.4 million, and milestone, license and royalty revenue of USD 5.1 million. Net loss attributable to common stockholders was USD 68.0 million in Q4 2025 (USD 0.78 per share) and USD 285.4 million in FY 2025 (USD 3.29 per share). R&D expense was USD 78.6 million in Q4 2025 and USD 258.8 million in FY 2025, while SG&A expense was USD 49.9 million in Q4 2025 and USD 179.7 million in FY 2025. Syndax ended 2025 with cash, cash equivalents and short-term investments of USD 394.1 million. On the business side, Revuforj prescriptions were approximately 1,150 in Q4 2025 (+35%) following the October 2025 FDA approval in R/R NPM1-mutated AML, and the company initiated the Phase 3 REVEAL-ND trial in newly diagnosed NPM1m AML in November 2025. For Niktimvo, Q4 2025 net revenue was USD 56.0 million (+22%) and FY 2025 net revenue was USD 151.6 million (as reported by partner Incyte), with Syndax recording 50% of net commercial profit as collaboration revenue. Syndax also said it completed enrollment in the Phase 2 MAXPIRe idiopathic pulmonary fibrosis trial in Q1 2026, with topline data expected in Q4 2026, and guided FY 2026 combined R&D plus SG&A expense of approximately USD 400 million, excluding an estimated USD 50 million of non-cash stock-based compensation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602261601PRIMZONEFULLFEED9662294) on February 26, 2026, and is solely responsible for the information contained therein.